Company / Accounts Receivable
Sonoma Pharmaceuticals, Inc. Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$2.2M
FY2025
5-year range
$2.2M / $2.9M
FY2021-FY2025
Trend
-23.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 9 years, ranging from $2M in FY2018 to $4M in FY2020.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -11.3%.
Declined from $3M to $2M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -2.5%
- 5-Year CAGR
- -11.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -11.3%, indicating a declining trend.
- In FY2025, accounts receivable decreased 23.0% year-over-year.
- Peak accounts receivable was recorded in FY2020.
- Lowest accounts receivable in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | - | - |
| FY2025 | $2.2M | -23.0% |
| FY2024 | $2.9M | +12.7% |
| FY2023 | $2.6M | +6.9% |
| FY2022 | $2.4M | -14.2% |
| FY2021 | $2.8M | -30.9% |
| FY2020 | $4.1M | +16.7% |
| FY2019 | $3.5M | +126.5% |
| FY2018 | $1.5M | -27.1% |
| FY2017 | $2.1M | -7.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026